Identification of 17-α-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6

Chemical Research in Toxicology

Volumn 19, Issue 2, 2006, Pages 279-287

  Kent, Ute M ^a   Lin, Hsia Lien ^a   Mills, Danielle E ^a,b   Regal, Kelly A ^a,c   Hollenberg, Paul F ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b PFIZER INC   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPROTEIN; CYTOCHROME P450; CYTOCHROME P450 2B1; CYTOCHROME P450 2B2; CYTOCHROME P450 2B4; CYTOCHROME P450 2B6; ETHINYLESTRADIOL; GLUTATHIONE; OXYGEN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVE SITE; ENZYME INACTIVATION; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; LIVER TOXICITY; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NEUROTOXICITY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN MODIFICATION; RAT;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2B1; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME ACTIVATION; ENZYME INHIBITORS; ETHINYL ESTRADIOL; GLUTATHIONE; HUMANS; MOLECULAR STRUCTURE; PEPTIDES; RATS; RATS, LONG-EVANS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 33644536707     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx050256o     Document Type: Article

References (42)

1. Omura, T., and Sato, R. (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its heme protein nature. J. Biol. Chem. 239, 2370-2378.
2. Guengerich, F. P. (2002) In Enzyme Systems That Metabolize Drugs and Other Xenobiotics (Ioannides, C., Ed.) pp 33-65, Wiley, New York.
3. LoPachin, R. M.; DeCaprio, A. P. (2005) Protein adduct formation as a molecular mechanism in neurotoxicity. Toxicol. Sci. 86, 214-225.
4. Wester, M. R., Johnson, E. F., Marques-Soares, C., Dijols, S., Dansette, P. M., Mansuy, D., and Stout, C. D. (2003) Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1 Å resolution: Evidence for an induced fit model of substrate binding. Biochemistry 42, 9335-9345.
5. Williams, P. A., Cosme, J., Sridar, V., Johnson, E. F., and McRee, D. E. (2000) Mammalian microsomal cytochrome P450 monooxygenase: Structural adaptations for membrane binding and functional diversity. Mol. Cell 5, 121-131.
6. Poulos, T. L., Finzel, B. C., and Howard, A. J. (1987) High-resolution crystal structure of cytochrome P450 cam. J. Mol. Biol. 195, 687-700.
7. Scott, E. E., White, M. A., He, Y. A., Johnson, E. F., Stout, C. D., and Halpert, J. R. (2004) Structure of mammalian cytochrome P450 2B4 complexed with 4-(4-chlorophenyl)imidazole at 1.9-Å resolution. J. Biol. Chem. 279, 27294-27301.
8. Williams, P. A., Cosme, J., Vinković, D. M., Ward, A., Angove, H. C., Day, P. J., Vonrhein, C., Tickle, I. J., and Jhoti, H. (2004) Crystal structure of human cytochrome P450 3A4 bound to metyraprone and progesterone. Science 305, 683-686.
9. Szklarz, G. D., and Halpert, J. R. (1997) Molecular modeling of cytochrome P450 3A4. J. Comput.-Aided Mol. Des. 11, 265-272.
10. Strobel, S. M., and Halpert, J. R. (1997) Reassessment of cytochrome P450 2B2: Catalytic specificity and identification of four active site residues. Biochemistry 36, 11697-11706.
11. Domanski, T. L., and Halpert, J. R. (2001) Analysis of mammalian cytochrome P450 structure and function by site-directed mutagenesis. Curr. Drug Metab. 2, 117-137.
12. Kent, U. M., Jushchyshyn, M. I., and Hollenberg, P. F. (2001) Mechanism-based inactivators as probes of cytochrome P450 structure and function. Curr. Drug Metab. 2, 215-243 (review).
13. Silverman, R. B. (1996) Mechanism-based enzyme inactivators. In Contemporary Enzyme Kinetics and Mechanisms (Purich, D. L., Ed.) pp 291-335, Academic Press, San Diego.
14. He, K., Falick, A. M., Chen, B., Nilsson, F., and Correia, M. A. (1996) Identification of the heme adduct and an active site peptide modified during mechanism-based inactivation of rat liver cytochrome P450 2B1 by secobarbital. Chem. Res. Toxicol. 9, 614-622.
15. 3H]-labeled 2-ethynylnaphthalene-inactivated P450 2B1 and 2B4 using amino acid sequencing and mass spectrometry. Biochemistry 33, 3766-3771.
16. Guengerich, F. P. (1988) Oxidation of 17α-ethynylestradiole by human liver cytochrome P-450. Mol. Pharmacol. 33, 500-508.
17. Kent, U. M., Mills, D. E., Rajnarayanan, R. V., Alworth, W. L., and Hollenberg, P. F. (2002) Effect of 17-α-ethynylestradiole on the activities of cytochrome P450 2B (P450 2B) enzymes: Characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites. J. Pharmacol. Exp. Ther. 300, 549-558.
18. Lin H.-L., Kent U. M., and Hollenberg, P. F. (2002) Mechanism-based inactivation of cytochrome P450 3A4 by 17-α-ethynylestradiole: Evidence for heme destruction and covalent binding to protein. J. Pharmacol. Exp. Ther. 301, 160-167.
19. Baillie, T. A., and Davis, M. R. (1993) Mass spectrometry in the analysis of glutathione conjugates. Biol. Mass Spectrom. 22, 319-325.
20. Jin, L., and Baillie, T. A. (1997) Metabolism of the chemoprotective agent diallyl sulfide to glutathione conjugates in rats. Chem. Res. Toxicol. 10, 318-327.
21. Evans D. C., Watt, A. P., Nicoll-Griffith, D. A., and Baillie, T. A. (2004) Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17, 3-16.
22. Saito, T., and Strobel, H. W. (1981) Purification to homogeneity and characterization of a form of cytochrome P450 with high specificity for benzopyrene from beta-naphthoflavone-pretreated rat liver microsomes. J. Biol. Chem. 256, 984-988.
23. Hanna, I. H., Teiber, J. F., Kokones, K. L., and Hollenberg, P. F. (1998) Role of alanine at position 363 of cytochrome P450 2B2 in influencing the NADPH- and hydroperoxide-supported activities. Arch. Biochem. Biophys. 350, 324-332.
24. Hanna, I. H., Reed, J. R., Guengerich, F. P., and Hollenberg P. F. (2000) Expression of human cytochrome P450 2B6 in Escherichia coli: Characterization of catalytic activity and expression in human liver. Arch. Biochem. Biophys. 376, 206-216.
25. Hanna, I. H., Roberts, E. S., and Hollenberg, P. F. (1998) Molecular basis for the difference in lidocain binding and the regioselectivity of oxidation by cytochrome P450 2B1 and 2B2. Biochemistry 37, 311-318.
26. Coon, M. J., va der Hoeven, T. A., Dahl, S. B., and Haugen, D. A. (1978) Two forms of liver microsomal cytochrome P450, P450 LM2 and P450 LM4 (rabbit liver). Methods Enzymol. 52, 109-117.
27. Buters, J. T., Schiller, C. D., and Chou, R. C. (1993) A highly sensitive tool for the assay of cytochrome P450 enzyme activity in rat, dog and man. Biochem. Pharmacol. 46, 1577-1584.
28. Regal, K. A., Schrag, M. L., Kent, U. M., Wienkers, L. C., and Hollenberg, P. F. (2000) Mechanism-based inactivation of the cytochrome P450 2B1 by 7-ethynylcoumarin: Verification of apo-P450 adduction by electrospray ion trap mass spectrometry. Chem. Res. Toxicol. 13, 262-270.
29. Gotoh, O. (1992) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analysis of amino acid and coding nucleotide sequences. J. Biol. Chem. 267, 83-90.
30. He, Y. Q., He, A. Y., and Halpert, J. R. (1995) Escherichia coli expression of site-directed mutants of cytochrome P450 2B1 from six substrate recognition sites: Substrate specificity and inhibitor selectivity studies. Chem. Res. Toxicol. 8, 574-579.
31. Wang, B., Sanchez, R. I., Franklin, R. B., Evans, D. C., and Huskey, S.-E. W. (2004) The involvement of CYP3A4 and CYP2C9 in the metabolism of 17α-ethynylestradiol. Drug Metab. Dispos. 32, 1209-1212.
32. Lin, H.-L., Kent, U. M., and Hollenberg, P. F. (2005) The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: Evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. J. Pharmacol. Exp. Ther. 313, 154-164.
33. Bateman, K. P., Baker, J., Wilke, M., Lee, J., LeRiche, T., Seto, C., Day, S., Chauret, N., Quellet, M., and Nicoll-Griffith, D. A. (2004) Detection of covalent adducts to cytochrome P450 3A4 using liquid chromatography mass spectrometry. Chem. Res. Toxicol. 17, 1356-1361.
34. Ortiz de Montellano, P. R., and Komives, E. A. (1985) Branchpoint for heme alkylation and metabolite formation in the oxidation of arylacetylenes by cytochrome P-450 J. Biol. Chem. 260, 3330-3336.
35. Correia, M. A., and Ortiz de Montellano, P. R. (2005) Inhibition of cytochrome P450 enzymes. In Cytochrome P450 Structure, Mechanism, and Biochemistry (Ortiz de Montellano, P. R., Ed.) pp 247-322, Kluwer Academic/Plenum Publishers, New York.
36. Abdel-Aziz, M. T., and Williams, K. I. H. Metabolism of 17α-ethynylestradiol and its 3-methyl ether by the rabbit; an in vivo D-homoannulation. (1969) Steroids 13, 809-820.
37. Abdel-Aziz, M. T., and Williams, K. I. H. (1970) Metabolism of radioactive 17α-ethynylestradiol by women. Steroids 15, 695-710.
38. Sisenwine, S. F., Kimmel, H. B., Liu, A. L., and Ruelius, H. W. (1978) The metabolic disposition of norgestrel in female rhesus monkeys. Drug Metab. Dispos. 7, 1-6.
39. Schmid, S. E., Au, W. Y. W., Hill, D. E., Kadubar, F. F., and Slikker, W., Jr. (1983) Cytochrome P-450-dependent oxidation of the 17α-ethynyl group of synthetic steroids. Drug Metab. Dispos. 11, 531-536.
40. Guengerich, F. P. (1990) Metabolism of 17α-ethynylestradiol in humans. Life Sci. 47, 1981-1988 (mini review).
41. Bolt, H. M., Kappus, H., and Remmer, H. (1973) Studies on the metabolism of ethynylestradiol in vitro and in vivo: The significance of 2-hydroxylation and the formation of polar products. Xenobiotica 773-785.
42. Scott, E. E., He, Y. A., Wester, M. R., White, M. A., Chin, C. C., Halpert, J. R., Johnson, E. F., and Stout, C. D. (2003) From the cover: An open conformation of mammalian cytochrome P450 2B4 at 1.6-Å resolution. Proc. Natl. Acad. Sci. U.S.A. 100, 13196-13201.